Veru (VERU) announced data from a meta-analysis presentation at ObesityWeek, which took place November 5, 2024, in San Antonio, Texas. Conclusions: Meta-analysis shows in older subjects with obesity that enobosarm 3mg daily treatment resulted in DEXA body composition changes of greater total weight loss by day 147 with preservation of lean mass and greater loss of fat. These data support the potential for enobosarm when combined with a GLP-1 RA to also preserve muscle, while preferentially reducing fat resulting in a higher quality weight loss in patients with obesity.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio